All In Biotech

Drug Trial Radar · NCT04349800

A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy Volunteers

A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of KVD900 Followed by Crossover Sub-studies of KVD900 Formulations, and Food Effect in Healthy Male Volunteers

Last checked: Nov 19, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

84

Actual

Start

Jan 4, 2018

Primary completion

Sep 10, 2018

Study completion Sep 10, 2018

Sponsor

Lead sponsor
KalVista Pharmaceuticals, Ltd.Industry
Sponsor type
Industry
First posted
Apr 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A safety, tolerability, pharmacokinetic and food effect study of KVD900 in healthy volunteers.

Conditions

  • Hereditary Angioedema

Interventions

  • KVD900Drug

    Active

  • Placebo to KVD900Drug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects with Adverse EventsTime frame: Change from pre-dose to last visit, 5-7 days post dose.
  2. Number of Subjects with Serious Adverse EventsTime frame: Change from pre-dose to last visit, 5-7 days post dose.
  3. Number of participants with clinically significant changes in laboratory assessmentsTime frame: Throughout study until last visit, 5-7 days post dose.
  4. Number of participants with clinically significant changes in vital signsTime frame: Throughout study until last visit, 5-7 days post dose.
  5. Number of participants with clinically significant changes in electrocardiogram (ECG) measurementsTime frame: Throughout study until last visit, 5-7 days post dose.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • KalVista Investigative Site

    Wales, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.